New triple-drug attack targets rare blood cancer
NCT ID NCT07464210
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) in people with Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to see how well the treatment shrinks tumors and controls the disease. About 19 adults who have not yet been treated for this condition will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug duo shows promise for rare blood cancer